Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Aged
Aged, 80 and over
Albumins
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Deoxycytidine
/ administration & dosage
Disease-Free Survival
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neutropenia
/ chemically induced
Paclitaxel
/ administration & dosage
Pancreatic Neoplasms
/ drug therapy
Retrospective Studies
Survival Rate
Gemcitabine
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 11 2020
06 11 2020
Historique:
received:
16
06
2020
accepted:
28
10
2020
entrez:
7
11
2020
pubmed:
8
11
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with first-line Nab-Gem were included in this retrospective analysis. Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale. Outcome measures were overall survival (OS), progression-free survival (PFS) and response rate. 115 patients were analyzed. Median PFS was 7 months (95% CI 5-8) for patients with grade ≥ 3 neutropenia and 6 months (95% CI 5-6) for patients with grade < 3 neutropenia [p = 0.08; hazard ratio (HR 0.68)]. Median OS was 13 months (95% CI 10-18) for patients with grade ≥ 3 neutropenia and 10 months (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44). In multivariate analysis, the occurrence of grade ≥ 3 neutropenia showed a statistically significant association with OS (HR 0.62; 95% CI 0.09-0.86; p = 0.05). Nab-Gem-induced neutropenia is associated with longer survival in metastatic pancreatic cancer patients.
Identifiants
pubmed: 33159172
doi: 10.1038/s41598-020-76465-9
pii: 10.1038/s41598-020-76465-9
pmc: PMC7648798
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Deoxycytidine
0W860991D6
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19281Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Cancer Res. 2002 May;8(5):1038-44
pubmed: 12006516
Ann Oncol. 2018 Sep 1;29(9):1903-1910
pubmed: 30099478
Clin Genitourin Cancer. 2018 Aug;16(4):318-324
pubmed: 29866495
J Clin Oncol. 2005 Nov 1;23(31):7785-93
pubmed: 16258082
Oncotarget. 2017 Apr 9;8(39):66593-66600
pubmed: 29029540
Oncotarget. 2020 Mar 10;11(10):924-941
pubmed: 32206189
Eur J Cancer. 2001 Sep;37(13):1590-8
pubmed: 11527683
BMC Cancer. 2019 Jan 8;19(1):40
pubmed: 30621618
Gastric Cancer. 2018 Mar;21(2):276-284
pubmed: 28634748
J Clin Oncol. 2018 Aug 20;36(24):2545-2556
pubmed: 29791286
Curr Oncol Rep. 2014 Feb;16(2):366
pubmed: 24445498
Mol Cancer Ther. 2017 Oct;16(10):2215-2222
pubmed: 28716815
Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):295-301
pubmed: 31607641
Oncotarget. 2015 Apr 10;6(10):8255-60
pubmed: 25779664
Ann Surg Oncol. 2006 Aug;13(8):1035-46
pubmed: 16865597
Pancreas. 2019 Feb;48(2):199-208
pubmed: 30589831
Anticancer Drugs. 2020 Jul;31(6):632-636
pubmed: 32011363
Curr Cancer Drug Targets. 2020 Sep 18;:
pubmed: 32957885
Ann Pharmacother. 1994 May;28(5 Suppl):S11-4
pubmed: 7915152
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
BMC Cancer. 2016 Sep 02;16(1):709
pubmed: 27590845
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Eur Urol. 2014 Jun;65(6):1198-204
pubmed: 23910941
Cancers (Basel). 2018 Nov 16;10(11):
pubmed: 30453583